Literature DB >> 12615298

Smallpox: a potential agent of bioterrorism.

Richard J Whitley1.   

Abstract

The events of 11 September 2001, in New York City, and subsequent identification of anthrax in the United States Postal System, have generated a new sense of awareness for the potential of biological terrorism, if not warfare. Among those agents identified by the Centers for Disease Control and Prevention as 'Class A Bioterrorist Threats', smallpox is among the most dangerous. The ease of transmission of this agent, the lack of immunity in the population at large to this agent, and rapidity of its spread, if released, all generate significant concern for its deployment. A vaccine directed against smallpox is available but it is also associated with significant adverse events-some of which are life-threatening. Further, no antiviral drug has proven efficacious for therapy of human disease, although one licensed drug, cidofovir, does have in vitro activity. Regardless, heightened awareness should lead to the development of a vaccine without significant adverse events and safe and efficacious antiviral drugs. The availability of a vaccine and antiviral drugs that are safe would significantly remove any major threat of smallpox deployment by a terrorist.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12615298     DOI: 10.1016/s0166-3542(02)00195-x

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  21 in total

1.  Detection of orthopoxvirus DNA by real-time PCR and identification of variola virus DNA by melting analysis.

Authors:  Andreas Nitsche; Heinz Ellerbrok; Georg Pauli
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

2.  Development and use of a vaccinia virus neutralization assay based on flow cytometric detection of green fluorescent protein.

Authors:  Patricia L Earl; Jeffrey L Americo; Bernard Moss
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

3.  Human antibody responses to the polyclonal Dryvax vaccine for smallpox prevention can be distinguished from responses to the monoclonal replacement vaccine ACAM2000.

Authors:  Christine Pugh; Sarah Keasey; Lawrence Korman; Phillip R Pittman; Robert G Ulrich
Journal:  Clin Vaccine Immunol       Date:  2014-04-23

4.  Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate.

Authors:  Wendy C Magee; Karl Y Hostetler; David H Evans
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

5.  Use of internally controlled real-time genome amplification for detection of variola virus and other orthopoxviruses infecting humans.

Authors:  C G Fedele; A Negredo; F Molero; M P Sánchez-Seco; A Tenorio
Journal:  J Clin Microbiol       Date:  2006-10-25       Impact factor: 5.948

Review 6.  Smallpox vaccines for biodefense.

Authors:  Richard B Kennedy; Inna Ovsyannikova; Gregory A Poland
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

7.  Comparative whole genome sequence analysis of wild-type and cidofovir-resistant monkeypoxvirus.

Authors:  Jason Farlow; Mohamed Ait Ichou; John Huggins; Sofi Ibrahim
Journal:  Virol J       Date:  2010-05-28       Impact factor: 4.099

8.  Mechanism of antiviral drug resistance of vaccinia virus: identification of residues in the viral DNA polymerase conferring differential resistance to antipoxvirus drugs.

Authors:  Don B Gammon; Robert Snoeck; Pierre Fiten; Marcela Krecmerová; Antonín Holý; Erik De Clercq; Ghislain Opdenakker; David H Evans; Graciela Andrei
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

9.  Surface-Dried Viruses Can Resist Glucoprotamin-Based Disinfection.

Authors:  Benjamin Zeitler; Ingrid Rapp
Journal:  Appl Environ Microbiol       Date:  2014-09-12       Impact factor: 4.792

10.  L1R, A27L, A33R and B5R vaccinia virus genes expressed by fowlpox recombinants as putative novel orthopoxvirus vaccines.

Authors:  Sole Maria Pacchioni; Massimiliano Bissa; Carlo Zanotto; Carlo De Giuli Morghen; Elena Illiano; Antonia Radaelli
Journal:  J Transl Med       Date:  2013-04-11       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.